Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of $1.40, $3.07 better than the analyst estimate of ($1.67). Revenue for the quarter came in at $96.12 million versus the consensus estimate of $80.89 million.

GUIDANCE:

Blueprint Medicines sees FY2024 revenue of $390-410 million, versus the consensus of $393 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.